Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial

IMPORTANCE: Standard molecularly based strategies to predict and/or prevent oral cancer development in patients with oral premalignant lesions (OPLs) are lacking. OBJECTIVE: To test if the epidermal growth factor receptor inhibitor erlotinib would reduce oral cancer development in patients with high...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: William, William N., Papadimitrakopoulou, Vassiliki, Lee, J. Jack, Mao, Li, Cohen, Ezra E.W., Lin, Heather Y., Gillenwater, Ann M., Martin, Jack W., Lingen, Mark W., Boyle, Jay O., Shin, Dong M., Vigneswaran, Nadarajah, Shinn, Nancy, Heymach, John V., Wistuba, Ignacio I., Tang, Ximing, Kim, Edward S., Saintigny, Pierre, Blair, Elizabeth A., Meiller, Timothy, Gutkind, J. Silvio, Myers, Jeffrey, El-Naggar, Adel, Lippman, Scott M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4771491/
https://ncbi.nlm.nih.gov/pubmed/26540028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2015.4364
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados